Immunoprecise Antibodies Ltd Cash Flow Conversion Efficiency
Immunoprecise Antibodies Ltd cash flow conversion efficiency. Based on the latest financial reports, Immunoprecise Antibodies Ltd (IPA) has a cash flow conversion efficiency ratio of -0.048x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($23.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immunoprecise Antibodies Ltd (1997–2025)
Cash flow conversion efficiency of Immunoprecise Antibodies Ltd from 1997 to 2025. This chart illustrates how Immunoprecise Antibodies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immunoprecise Antibodies Ltd share price for real-time trading data and today's change.
Immunoprecise Antibodies Ltd Cash Flow Conversion Ratio Explained
Immunoprecise Antibodies Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunoprecise Antibodies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunoprecise Antibodies Ltd ranked by their cash flow conversion efficiency. Also see market value of Immunoprecise Antibodies Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Intech Biopharm Ltd
TWO:6461
|
-0.085x |
|
I-Berhad
KLSE:4251
|
0.032x |
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
-0.143x |
|
Podak Co Ltd
TWO:3537
|
0.023x |
|
Doktas Dokumculuk Ticaret ve Sanayi AS
IS:DOKTA
|
0.066x |
|
Kino Polska TV SA
WAR:KPL
|
0.081x |
|
Leifheit Aktiengesellschaft
F:LEI
|
0.079x |
Annual Cash Flow Conversion Efficiency for Immunoprecise Antibodies Ltd (1997–2025)
The table below shows the annual cash flow conversion efficiency of Immunoprecise Antibodies Ltd from 1997 to 2025. Review Immunoprecise Antibodies Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -160.37% |
| 2022-04-30 | $75.28 Million | $-9.92 Million | -0.132x | -1150.23% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +318.14% |
| 2011-04-30 | $158.40K | $-80.39K | -0.507x | -793.11% |
| 2010-04-30 | $5.43 Million | $-308.49K | -0.057x | -147.62% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -86.65% |
| 2007-04-30 | $5.43 Million | $-297.31K | -0.055x | -93.48% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +33.99% |
| 2003-04-30 | $867.54K | $-168.38K | -0.194x | +52.10% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more